Tonghua Dongbao Biotechnology Co., Ltd.

To compare the effectiveness of DB101 and adalimumab injection (Humira®) in the treatment of plaque psoriasis and determine whether the two have equivalent efficacy; to evaluate and compare the safety, tolerability, immunogenicity, and pharmacokinetic characteristics of DB101 and adalimumab injection (Humira®) in the treatment of plaque psoriasis.

The primary objective is to compare the pharmacokinetic similarity of the investigational drug DB101 and the reference drug Humira® after a single subcutaneous injection in healthy Chinese subjects; the secondary objective is to compare the safety and immunogenicity of the investigational drug DB101 and the reference drug Humira® after a single subcutaneous injection in healthy Chinese subjects.